Court Opinion

ID: 2641372
Source: CourtListenerOpinion
Date Created: 2013-11-07 01:01:39.672904+00
Date Added: 2024-06-11T12:27:50.244199
License: Public Domain

NOTE: This disposition is nonprecedential.

  United States Court of Appeals
      for the Federal Circuit
                ______________________

    E8 PHARMACEUTICALS, LLC AND THE
MASSACHUSETTS INSTITUTE OF TECHNOLOGY,
            Plaintiffs-Appellants,

                           v.

    AFFYMETRIX, INC. AND NAVIGENICS, INC.,
             Defendants-Appellees.
            ______________________

                      2013-1046
                ______________________

    Appeal from the United States District Court for the
District of Massachusetts in consolidated No. 08-CV-
11132, Judge George A. O'Toole, Jr.
                ______________________

              Decided: November 6, 2013
               ______________________

   JOHN B. WYSS, Wiley Rein LLP, of Washington, DC,
argued for plaintiffs-appellants. With him on the brief
were JAMES H. WALLACE, JR., MARK A. PACELLA, and
GREGORY R. LYONS.

    PETER E. ROOT, Kaye Scholer LLP, of Palo Alto, Cali-
fornia, argued for defendants-appellees. With him on the
brief were MICHAEL J. MALECEK, SEAN M. BOYLE, and
GARY ROSS ALLEN.
2              E8 PHARMACEUTICALS, LLC   v. AFFYMETRIX, INC.

                 ______________________

     Before LOURIE, DYK, and O’MALLEY, Circuit Judges.
PER CURIAM.
    We affirm the judgment of noninfringement in favor
of Affymetrix, Inc. and Navigenics, Inc. We base our
decision solely on our agreement with the district court’s
construction of the phrase “randomly primed PCR-derived
RCG.” We do not reach any other issues raised on appeal.
                      AFFIRMED